Immunonkologie

Prof. Dr. Marion Subklewe

Ravandi F et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory AML.
Usmani SZ et al. Phase I study of Teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Luke JJ et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD 1 and LAG 3, in patients with unresectable or metastatic neoplasms.
Zhao H et al. The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.

Prof. Dr. Mascha Binder

Olsson-Brown AC et al. Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series.
Anscher MS et al. Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A U.S. Food and Drug Administration pooled analysis.
O’Neal RL et al. Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.

Prof. Dr. Dimitrios Mougiakakos

Newman H et al. CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).
Wang X et al. Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).
Zhang Y et al. Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with relapsed/refractory non-Hodgkin lymphoma.
Osborne W et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with Pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
Berdeja JG et al. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

Immunonkologie Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite